InsidersTradesSigma
申报总数
公司
▲ 买入（0 笔）
▼ 卖出（2 笔）
内部人交易记录
董事已披露买入
0
已披露卖出
2
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Browse the full record of transactions filed by Papadopoulos Stelios, 董事. Insider active across 4 companies, notably Exelixis, INC.. Cumulatively, 20 filings have been published. Split: 0 buy · 2 sells. Total volume traded: €5.2m. Activity tracked since 11 May 2021. The latest transaction was disclosed on 27 May 2026 (Attribution). Regulator: SEC (Form 4). All data is free.
Companies and markets linked to Papadopoulos Stelios
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报20 总计
8,367 股0Common StockSEC:0000939767-26-000083:0
17,578 股@ US$2.56100.0% 占其流量Common StockSEC:0001202098-26-000004:0
100,000 股@ US$43.5562.6% 占其流量Common StockSEC:0000939767-25-000137:0
976,253 股Common StockSEC:0000950170-25-091032:0
9,812 股0Common StockSEC:0000939767-25-000088:0
20,634 股@ US$19.7714.9% 占其流量Common StockSEC:0000939767-25-000080:0
62,500 股0Common StockSEC:0000950170-25-061119:0
18,838 股0Common StockSEC:0000939767-24-000102:0
11,686 股@ US$19.578.6% 占其流量Common StockSEC:0000939767-24-000075:0
250,000 股@ US$1.6018.6% 占其流量Common StockSEC:0000950170-24-032213:0
20,718 股0Common StockSEC:0000939767-23-000056:0
222,198 股@ US$0.90019.2% 占其流量Common StockSEC:0001209191-23-024329:0
2,255 股0Common StockSEC:0001127602-22-017806:0
19,575 股0Common StockSEC:0000939767-22-000079:0
84,515 股@ US$19.560.013% mcap77.9% 占其流量Common StockSEC:0000939767-22-000031:0
2,222,222 股@ US$0.3656.5% 占其流量Common StockSEC:0001209191-21-067264:0
1,275 股0Common StockSEC:0001127602-21-021336:0
16,424 股0Common StockSEC:0000939767-21-000063:0
40,000 股@ US$6.303.5% 占其流量Common StockSEC:0000939767-21-000049:0
15,071 股Common StockSEC:0000939767-16-000129:0
20 条申报中的 20 条
About Papadopoulos Stelios
Administrateur, a declarant with 20 filings in total. Among the sampled recent filings from 2016-01-05 to 2026-05-29, sells total EUR 5220048, with no buys reported, and the modal transaction nature is Attribution. The main filings concern Exelixis, INC., Regulus Therapeutics Inc., BIOGEN INC. and Ovid Therapeutics Inc.
